Vascular Intervention Innovation Forum: The Robust Momentum of Vascular Intervention and the Path Toward High-Quality Development
Against the backdrop of an aging population, China’s vascular interventional device market remains in a phase of steady growth. Although the national centralized procurement of coronary stents implemented in 2021 slowed the market’s growth rate, the industry’s growth drivers are shifting from cardiovascular intervention to neurointervention and peripheral vascular intervention as the competitive landscape evolves. Consequently, the market size of vascular interventional devices in China is expected to maintain its upward trajectory.
With strong policy support from the Chinese government, domestic vascular interventional device companies will continue to increase their R&D investment. The future market for import substitution of vascular interventional devices in China is vast, and the industry has significant growth potential. Centralized procurement has changed the competitive factors and industry landscape of the vascular interventional sector. In the short term, corporate profit margins have been significantly compressed; overall, this trend favors the formation and expansion of leading enterprises, some of which have begun to expand overseas. Meanwhile, centralized procurement has stimulated innovation among companies and accelerated product development.
This forum will invite clinical experts, leading industry enterprises, and investment institutions to comprehensively discuss technological innovations, research and current clinical practices, product landscapes, and development trends in vascular interventional therapy from their respective perspectives.
I.Forum Highlights
(I)Industry Outlook: Future Directions in Vascular Interventional Therapy
In recent years, significant advances have been made in the treatment of cardiovascular diseases. What changes will occur in the next decade? Known asHow Is Structural Heart Disease, the “Fourth Growth Point” of Interventional Cardiology, Developing? The “Chinese Power” Under Globalized Interventional MedicineWhat roles will be played on the global stage? How will multinational corporations implement localization strategies? Centered on these questions, this forum plans to invite clinical experts, academic scholars, and benchmark enterprises to participate. Furthermore, VCBeat will release the “Structural Heart Disease” report at the forum, aiming to present a comprehensive overview of the industry, identify key variables in the sector, and outline current challenges as well as future possibilities.
(II)Frontiers in Technology: A Collection of Hot Topics Including Structural Heart Disease, Interventional Artificial Hearts, Electrophysiological PFA, and Minimally Invasive Tumor Interventions
China’s vascular interventional device industry has established a relatively complete supply chain. Supported by favorable policies and funding, manufacturers have continuously enhanced their R&D and innovation capabilities. Structural heart disease has emerged as the fastest-growing segment within the cardiovascular intervention field in recent years, with substantial market opportunities and development potential injecting vibrant energy into this sector. Meanwhile, in August 2022, China completed its first implantation of a domestically developed transcatheter artificial heart, drawing extensive attention from clinicians. In the current field of cardiac electrophysiology, Pulsed Field Ablation (PFA) technology is one of the most prominent areas of focus. This forum will address hot topics such as structural heart disease, transcatheter artificial hearts, electrophysiological PFA, and minimally invasive tumor interventions. It will invite leading industry enterprises to share their experiences on cutting-edge subjects, including technological pathway selection for transcatheter artificial hearts, innovative diagnostic and therapeutic techniques for structural heart disease integrating “cardiovascular devices + AI + services,” and future development directions for minimally invasive tumor interventions.
(3)Market Applications: New Industry Opportunities from a Venture Capital Perspective and Challenges Amid the Centralized Procurement Storm
Driven by policy and market factors, capital continues to flow into the vascular medicine sector, providing impetus for innovative corporate development. In recent years, the heart failure market has gradually become the largest cardiovascular market after coronary and valvular diseases, being referred to as “The Final Battlefield for Heart Disease,” This ForumSenior venture capital and private equity representatives will be invited to share insights on the multi-billion-dollar heart failure management market and new opportunities in the fiercely competitive vascular interventional robotics sector. Meanwhile, as domestic companies achieve technological breakthroughs in vascular intervention and such diagnostic and therapeutic procedures become increasingly widespread, the localization of vascular interventional devices in China is expected to accelerate. The forum will also bring together stakeholders across the industry chain to discuss current trends, as well as the challenges and prospects for the vascular intervention market amid the wave of centralized procurement.
II.ForumIntroduction
ForumTime:May 5–7, 2023
ForumLocation:Shanghai · Zhangjiang Science Hall
Forum Name:Frontiers in Vascular Interventional Innovation Forum
Corporate Representatives in Attendance:Aikemai, Feidun Medical, Keruichi, Shengde Medical
※ Listed in alphabetical order by company name; rankings are not indicative of priority. Additional companies are being continuously verified.
ForumAgendaPlanning:
Outlook on the Direction of Cardiovascular Interventional Therapy in the Next Decade
"Structural Heart Disease" Report Released
"Chinese Power" in the Context of Globalization
Innovation-Driven Development Engine: Building a Leading Platform for Minimally Invasive Interventional Oncology
"Cardiovascular Devices + AI + Services": An Industrialization Platform for Innovative Structural Heart Disease Diagnosis and Treatment Technologies
Reflections on the Wave of Domestic Substitution Initiated by the Upgrade of Electrophysiology PFA Technology
Research and Development Progress and Future Prospects of Minimally Invasive Artificial Hearts
The Final Battlefield: A Multi-Billion-Yuan Heart Failure Management Market Welcomes New Opportunities
Challenges and Outlook for the Vascular Intervention Market Amid the Centralized Procurement Storm
※ Proposed agenda items are for reference only; final agenda items are subject to on-site confirmation.
